2015. ISPOR European Congress – Results of a Dutch Cost-Effectiveness Model of Radium-223 in Comparison to Cabazitaxel, Abiraterone, and Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Docetaxel

Gaultney J, Baka A, Leliveld-Kors A, Noordzij W, Wyndaele D, De Meyer C. Results of a Dutch Cost-Effectiveness Model of Radium-223 in Comparison to Cabazitaxel, Abiraterone, and Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Docetaxel. Value Health. 2015 Nov;18(7):A459. Presented at: ISPOR 18th Annual European Congress; November 9, 2015; Milan, Italy.